CD38 and Its Role in Ischemic Stroke
Author Information
Author(s): Choe Chi-un, Lardong Kerstin, Gelderblom Mathias, Ludewig Peter, Leypoldt Frank, Koch-Nolte Friedrich, Gerloff Christian, Magnus Tim
Primary Institution: University Hospital Hamburg-Eppendorf, Hamburg, Germany
Hypothesis
CD38 influences cytokine production, inflammation, and brain injury after focal cerebral ischemia.
Conclusion
CD38 deficiency reduces postischemic inflammation and brain injury, suggesting it could be a therapeutic target in ischemic stroke.
Supporting Evidence
- CD38-deficient mice showed less MCP-1 production after stroke compared to wildtype mice.
- Fewer immune cells infiltrated the brains of CD38-deficient mice after ischemic stroke.
- CD38 deficiency resulted in smaller infarct sizes and less neurological impairment.
Takeaway
This study found that a protein called CD38 makes brain injuries worse after a stroke, so blocking it might help people recover better.
Methodology
The study used a mouse model of ischemic stroke to compare CD38-deficient and wildtype mice, analyzing cytokine levels and immune cell infiltration.
Participant Demographics
C57BL/6 male mice, 12–15 weeks old.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website